FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2903103666> ?p ?o ?g. }

• W2903103666 endingPage "1160" @default.
• W2903103666 startingPage "1150" @default.
• W2903103666 abstract "Intravenous cyclophosphamide pulse, a standard treatment for systemic sclerosis (SSc)-related interstitial lung disease, elicits a disease-modifying effect on SSc vasculopathy, such as fostering microvascular de-remodeling. To investigate the molecular mechanism by which cyclophosphamide mitigates SSc vasculopathy, we employed endothelial cell–specific Fli1 knockout mice that mimic the functional and structural vascular abnormalities characteristic of SSc. Biweekly cyclophosphamide injection improved vascular permeability and structural abnormalities of endothelial cell–specific Fli1 knockout mice in 2 weeks and in 3 months, respectively. In endothelial cell–specific Fli1 knockout mice, a single dose of cyclophosphamide was sufficient to normalize the decreased expression of α–smooth muscle actin in dermal blood vessels and improve the impaired neovascularization in skin-embedded Matrigel plug. Under the same condition, the decreased expression of vascular endothelial cadherin, platelet-derived growth factor B, S1P1, and CCN1 (molecules associated with angiogenesis and/or vasculogenesis) was reversed along with the reversal of endothelial Fli1 expression. In SSc patients, serum CCN1 levels were significantly increased after intravenous cyclophosphamide pulse. Taken together, these results indicate that cyclophosphamide improves Fli1 deficiency-dependent vascular changes by normalizing the expression of angiogenesis- and vasculogenesis-related molecules and endothelial Fli1, which may help to explain the beneficial effect of cyclophosphamide on SSc vasculopathy. Intravenous cyclophosphamide pulse, a standard treatment for systemic sclerosis (SSc)-related interstitial lung disease, elicits a disease-modifying effect on SSc vasculopathy, such as fostering microvascular de-remodeling. To investigate the molecular mechanism by which cyclophosphamide mitigates SSc vasculopathy, we employed endothelial cell–specific Fli1 knockout mice that mimic the functional and structural vascular abnormalities characteristic of SSc. Biweekly cyclophosphamide injection improved vascular permeability and structural abnormalities of endothelial cell–specific Fli1 knockout mice in 2 weeks and in 3 months, respectively. In endothelial cell–specific Fli1 knockout mice, a single dose of cyclophosphamide was sufficient to normalize the decreased expression of α–smooth muscle actin in dermal blood vessels and improve the impaired neovascularization in skin-embedded Matrigel plug. Under the same condition, the decreased expression of vascular endothelial cadherin, platelet-derived growth factor B, S1P1, and CCN1 (molecules associated with angiogenesis and/or vasculogenesis) was reversed along with the reversal of endothelial Fli1 expression. In SSc patients, serum CCN1 levels were significantly increased after intravenous cyclophosphamide pulse. Taken together, these results indicate that cyclophosphamide improves Fli1 deficiency-dependent vascular changes by normalizing the expression of angiogenesis- and vasculogenesis-related molecules and endothelial Fli1, which may help to explain the beneficial effect of cyclophosphamide on SSc vasculopathy." @default.
• W2903103666 created "2018-12-11" @default.
• W2903103666 creator A5002430890 @default.
• W2903103666 creator A5007508591 @default.
• W2903103666 creator A5009161482 @default.
• W2903103666 creator A5019299627 @default.
• W2903103666 creator A5024535565 @default.
• W2903103666 creator A5024903237 @default.
• W2903103666 creator A5038365838 @default.
• W2903103666 creator A5051641852 @default.
• W2903103666 creator A5055921747 @default.
• W2903103666 creator A5079724790 @default.
• W2903103666 creator A5088566516 @default.
• W2903103666 date "2019-05-01" @default.
• W2903103666 modified "2023-10-04" @default.
• W2903103666 title "Cyclophosphamide Pulse Therapy Normalizes Vascular Abnormalities in a Mouse Model of Systemic Sclerosis Vasculopathy" @default.
• W2903103666 cites W1890624110 @default.
• W2903103666 cites W1899609713 @default.
• W2903103666 cites W1913137022 @default.
• W2903103666 cites W1983544560 @default.
• W2903103666 cites W1984831138 @default.
• W2903103666 cites W1986754716 @default.
• W2903103666 cites W1992251962 @default.
• W2903103666 cites W2021961134 @default.
• W2903103666 cites W2025012694 @default.
• W2903103666 cites W2042052097 @default.
• W2903103666 cites W2052537256 @default.
• W2903103666 cites W2056884098 @default.
• W2903103666 cites W2064855387 @default.
• W2903103666 cites W2067451663 @default.
• W2903103666 cites W2070446047 @default.
• W2903103666 cites W2076895382 @default.
• W2903103666 cites W2089969972 @default.
• W2903103666 cites W2094955298 @default.
• W2903103666 cites W2097931069 @default.
• W2903103666 cites W2103480365 @default.
• W2903103666 cites W2123401611 @default.
• W2903103666 cites W2125881724 @default.
• W2903103666 cites W2128073554 @default.
• W2903103666 cites W2131982212 @default.
• W2903103666 cites W2134681704 @default.
• W2903103666 cites W2136675526 @default.
• W2903103666 cites W2137049683 @default.
• W2903103666 cites W2138183967 @default.
• W2903103666 cites W2149839143 @default.
• W2903103666 cites W2154576801 @default.
• W2903103666 cites W2155144124 @default.
• W2903103666 cites W2163789792 @default.
• W2903103666 cites W2209243337 @default.
• W2903103666 cites W2252334125 @default.
• W2903103666 cites W2338216138 @default.
• W2903103666 cites W2396463232 @default.
• W2903103666 cites W2403038718 @default.
• W2903103666 cites W2416994986 @default.
• W2903103666 cites W2422507940 @default.
• W2903103666 cites W2590491928 @default.
• W2903103666 cites W2600657400 @default.
• W2903103666 cites W2604566416 @default.
• W2903103666 cites W2614338137 @default.
• W2903103666 cites W2754536921 @default.
• W2903103666 cites W2765167973 @default.
• W2903103666 cites W2894165655 @default.
• W2903103666 cites W4230768669 @default.
• W2903103666 cites W4237651240 @default.
• W2903103666 cites W4248278769 @default.
• W2903103666 cites W788792429 @default.
• W2903103666 cites W809327241 @default.
• W2903103666 cites W92170281 @default.
• W2903103666 doi "https://doi.org/10.1016/j.jid.2018.11.016" @default.
• W2903103666 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6604062" @default.
• W2903103666 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30508546" @default.
• W2903103666 hasPublicationYear "2019" @default.
• W2903103666 type Work @default.
• W2903103666 sameAs 2903103666 @default.
• W2903103666 citedByCount "3" @default.
• W2903103666 countsByYear W29031036662021 @default.
• W2903103666 countsByYear W29031036662023 @default.
• W2903103666 crossrefType "journal-article" @default.
• W2903103666 hasAuthorship W2903103666A5002430890 @default.
• W2903103666 hasAuthorship W2903103666A5007508591 @default.
• W2903103666 hasAuthorship W2903103666A5009161482 @default.
• W2903103666 hasAuthorship W2903103666A5019299627 @default.
• W2903103666 hasAuthorship W2903103666A5024535565 @default.
• W2903103666 hasAuthorship W2903103666A5024903237 @default.
• W2903103666 hasAuthorship W2903103666A5038365838 @default.
• W2903103666 hasAuthorship W2903103666A5051641852 @default.
• W2903103666 hasAuthorship W2903103666A5055921747 @default.
• W2903103666 hasAuthorship W2903103666A5079724790 @default.
• W2903103666 hasAuthorship W2903103666A5088566516 @default.
• W2903103666 hasBestOaLocation W29031036661 @default.
• W2903103666 hasConcept C104317684 @default.
• W2903103666 hasConcept C123012128 @default.
• W2903103666 hasConcept C126322002 @default.
• W2903103666 hasConcept C138626823 @default.
• W2903103666 hasConcept C142724271 @default.
• W2903103666 hasConcept C202751555 @default.
• W2903103666 hasConcept C203014093 @default.
• W2903103666 hasConcept C2776694085 @default.

• next